A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

231

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

April 16, 2025

Study Completion Date

April 16, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

Risankizumab

• Subcutaneous Injection via prefilled syringe

Trial Locations (3)

Acpru /Id# 270152, Grayslake

Collaborative Neuroscience Research CNS /ID# 270286, Los Alamitos

Cenexel Act /ID# 270310, Anaheim